International Leukemia Target Board for children with relapsed hematologic malignancies
International Concerted Action to Allocate Children, Adolescents and Young Adults With Relapsed and Refractory Leukemia/Lymphoma to the Right Therapy.
This study is trying to find the best treatment options for children with relapsed blood cancers by looking at their unique disease characteristics and how they respond to different drugs.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 0 Years to 25 Years |
| Sex | All |
| Sponsor | Princess Maxima Center for Pediatric Oncology Academic / other |
| Drugs / interventions | CAR-T, CAR T, CART, chemotherapy, immunotherapy |
| Locations | 7 sites (Ghent and 6 other locations) |
| Trial ID | NCT05270096 on ClinicalTrials.gov |
What this trial studies
The International Leukemia Target Board (iLTB) is a collaborative initiative aimed at prioritizing treatment options for children with relapsed or refractory hematological malignancies. This observational project brings together a multidisciplinary team of experts to analyze molecular and immunophenotypic data, as well as drug response profiles, to guide treatment decisions. The iLTB will monitor the implementation of its recommendations and track patient outcomes, providing valuable insights into the effectiveness of various treatment strategies. By harmonizing approaches across Europe, the iLTB seeks to improve the management of complex cases in pediatric oncology.
Who should consider this trial
Good fit: Ideal candidates for this initiative are children under 25 years old with a diagnosis of relapsed or refractory hematological malignancy who have undergone molecular profiling.
Not a fit: Patients currently receiving standard of care treatment or those without available molecular profiling results may not benefit from this initiative.
Why it matters
Potential benefit: If successful, this initiative could lead to more personalized and effective treatment strategies for children with challenging hematological malignancies.
How similar studies have performed: While similar collaborative tumor board approaches have been utilized, the iLTB represents a novel effort specifically targeting pediatric relapsed hematological malignancies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria 1. The patient has been diagnosed with a R/R hematological malignancy; 2. The patient is less than 18 years of age at the time of first diagnosis and less than 25 years at the time of inclusion with relapse/refractory hematological malignancy; 3. The patient is treated in a pediatric/AYA setting or study protocol, with no current standard of care treatment; 4. The patients' life expectancy is at least 6 weeks; 5. The patient has undergone any sort of molecular profiling of his/her tumor and the re-sults of this analysis are available; 6. The patient has undergone flow cytometry in a certified lab and results are available; 7. Written informed consent of patient and/or parent(s)/guardian(s) to discuss the patient in the iLTB according to local law and legislation has been obtained. Exclusion criteria: none defined
Where this trial is running
Ghent and 6 other locations
- UH Gent — Ghent, Belgium (Recruiting)
- Righospitalet — Copenhagen, Denmark (Recruiting)
- Semmelweis — Budapest, Hungary (Recruiting)
- Princess Máxima Center for Pediatric Oncology — Utrecht, Utrecht, Netherlands (Recruiting)
- Vall d'Hebron — Barcelona, Spain (Recruiting)
- Queen Silvia — Gothenburg, Sweden (Recruiting)
- Newcastle Hospital — Newcastle, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Michel Zwaan, Prof. dr. — Princess Maxima Center for Pediatric Oncology
- Study coordinator: Uri Ilan, MD
- Email: iltb@prinsesmaximacentrum.nl
- Phone: +31889725206
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.